Lymphoma in the News: Post-Traumatic Stress Symptoms are Common in Survivors of Non-Hodgkin Lymphoma

By Peter Martin, MD

Post-traumatic stress disorder (PTSD) is a chronic condition characterized by anxiety and re-experiencing of a particularly stressful psychological trauma. Typically, we associate PTSD with events like wars or serious accidents. There is increasing data, however, that survivors of serious medical illness can also be affected by symptoms of PTSD. Long-term results of a study designed to evaluate PTSD in survivors of non-Hodgkin lymphoma (NHL) were recently reported in the Journal of Clinical Oncology.

The investigators administered surveys to 886 individuals with a history of NHL. They found that 39% of patients experienced PTSD symptoms with 8% meeting diagnostic criteria for PTSD. In a follow up study performed five years later, 566 of the original group of patients responded to a second survey. The investigators found that roughly one-third of patients experienced persisting or worsening PTSD symptoms. Only 12% of patients had symptoms that resolved over the course of the study. People most likely to experience persistent or worsening symptoms of PTSD were those with a lower annual income and those that reported a negative impact from the cancer (e.g., appearance concerns, body changes, life interferences, worry).

These results are particularly concerning for two reasons. First, the assumption that cancer-related anxiety will improve over time appears to be flawed. Second, as the population of patients with cancer ages, and as cancer care becomes more expensive, we are likely to see an increase in persistent PTSD symptoms. Clearly, we need to find ways to improve the initial cancer experience and to intervene earlier in patients at risk of persistent PTSD symptoms. The statement “survivorship begins at diagnosis” appears to be truer than ever.

Follicular Lymphoma Clinical Trial

Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients with Follicular Lymphoma

Update: this study is closed to enrollment. 

Monoclonal antibodies can fight lymphoma by binding to proteins expressed on lymphoma cells and either directly killing or inducing the immune system to kill the tumor cells.

With radioimmunotherapy, the antibody is labeled with a radioactive molecule, allowing directed delivery of radiation to the lymphoma.  Radioimmunotherapy is effective in follicular lymphoma, but immune reactions against the radiolabeled antibody have limited the utility of this approach.

In this study, we are evaluating the combination of an unlabeled antibody to one lymphoma-associated protein (CD20) with a radio-labeled antibody to a different lymphoma-associated protein (CD22), in hopes of improving responses. The antibodies are modified to minimize immune responses, and both antibodies will be given in repeated doses in order to increase the total amount of drug administered while limiting side effects.

Eligibility:

  • Follicular lymphoma
  • No more than 2 prior systemic treatments for non-Hodgkin’s lymphoma
  • Detailed eligibility discussed when you contact the study team

For more information, contact June Greenberg, RN at (212) 746-2651 or jdg2002@med.cornell.edu.

Click here to view all lymphoma clinical trials at Weill Cornell Medical Center.

Clinical Trial Available for Untreated DLBCL

Early Response Assessment in Patients with Diffuse Large B-Cell Lymphoma Using 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET)

Update: this study is closed to enrollment. 

Although many patients with diffuse large B cell lymphoma are cured with initial treatment, some patients do not respond well to therapy, or they relapse after an initial response. Certain factors have been shown to predict the probability of responding well, but they are not able to define whether an individual patient will respond well to treatment.

In this study, we are examining the ability of FDG-PET scanning early on in treatment to predict the ultimate outcome of that treatment in an individual patient. We hope to use the information gained in this study to individualize treatment in the future.

Key eligibility:

  • Diagnosis of CD20+ diffuse large B-cell lymphoma (DLBCL) of any stage, including subtypes:
  • Mediastinal large B-cell
  • Centroblastic
  • Immunoblastic
  • T-cell rich B-cellmed
  • Anaplastic B-cell lymphoma
  • No prior anti-lymphoma therapy

Click here for a more detailed description of this study or contact June Greenberg, RN at (212) 746-2651 or jdg2002@med.cornell.edu.